4.71

1.51% +0.07

Pre-market: 4.82 0.11 +2.34%

Zura Bio Ltd (ZURA)

Overview News Price History Discussions Forecast

Zura Bio Ltd stock is currently priced at $4.71, with a 24-hour trading volume of 92,848. It has seen a +1.51% increased in the last 24 hours and a +67.62% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $4.63 pivot point. If it approaches the $4.75 resistance level, significant changes may occur.

Previous Close:

$4.64

Open:

$4.56

24h Volume:

92,848

Market Cap:

$293.56M

Revenue:

Net Income/Loss:

$-60.36M

P/E Ratio:

-1.1248

EPS:

-4.1875

Net Cash Flow:

$-15.05M

1W Performance:

+13.49%

1M Performance:

+67.62%

6M Performance:

+6.32%

1Y Performance:

-7.47%

1D Range:

$4.56

$4.88

52W Range:

$2.00

$14.00

Zura Bio Ltd Stock (ZURA) Company Profile

Name

Zura Bio Ltd

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

858-247-0520

Address

4225 Executive Square, Suite 600, San Diego

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ZURA's Discussions on Twitter

Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-25-23	Initiated	Oppenheimer	Outperform
Jun-22-23	Initiated	Guggenheim	Buy
Jun-14-23	Initiated	Chardan Capital Markets	Buy
May-24-23	Initiated	Raymond James	Strong Buy

Zura Bio Ltd Stock (ZURA) Financials Data

Zura Bio Ltd (ZURA) Net Income 2024

ZURA net income (TTM) was -$60.36 million for the quarter ending December 31, 2023.

Zura Bio Ltd (ZURA) Cash Flow 2024

ZURA recorded a free cash flow (TTM) of -$15.05 million for the quarter ending December 31, 2023.

Zura Bio Ltd (ZURA) Earnings per Share 2024

ZURA earnings per share (TTM) was -$4.394 for the quarter ending December 31, 2023.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.